Stockscreener 앱 받기
256.46
1.44%
-3.75
시간 외 거래:
256.53
0.07
+0.03%
Abbvie Inc 주식(ABBV)의 최신 뉴스
Mary Kuriakose Starts New Oncology Leadership Role at AbbVie - Oncodaily
AbbVie Inc. stock holds near highs as Apogee deal and guidance support sentiment - ad-hoc-news.de
Key deals this week: Flex, Nvidia, AbbVie and more (VRT:NYSE) - Seeking Alpha
Michael Henderson: A New Chapter Begins for Apogee Therapeutics With AbbVie - Oncodaily
Scotiabank Remains a Buy on AbbVie (ABBV) - The Globe and Mail
AbbVie-allied ADARx aims to go public with 3 drugs in the clinic - Endpoints News
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Trailing rivals, AbbVie scores win with dual-acting myeloma drug - BioPharma Dive
AbbVie Inc. stock gains on Apogee deal and reaffirmed 2026 guidance - ad-hoc-news.de
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study - Yahoo Finance
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing? - Yahoo Finance
The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge - Yahoo Finance
AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma - Yahoo Finance
AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis) - Seeking Alpha
AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story - Yahoo Finance
AbbVie-owned Apogee Therapeutics (APGE) pulls unsold stock - Stock Titan
CFO of Apogee Therapeutics (APGE) gives up last shares in AbbVie buyout - Stock Titan
AbbVie's Etentamig Delivers 74% Response Rate in Pivotal Cancer Trial - Yahoo Finance
AbbVie’s Etentamig Suits Community Setting With Monthly Dosing, Low Toxicity - insights.citeline.com
AbbVie Completes $10.9 Billion Acquisition Of Apogee Therapeutics - Pulse 2.0
Top Analyst Reports for Amazon, AbbVie & Alibaba - Yahoo Finance
AbbVie Touts Positive Data For Multiple Myeloma DrugAbbVie (NYSE:ABBV) - Benzinga
AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline - Dermatology Times
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care? - Trefis
AbbVie's etentamig hits dual primary endpoints in Phase III relapsed/refractory multiple myeloma trial - The Pharma Letter
AbbVie's blood cancer therapy lowers disease progression, death risk in trial - Reuters
ABBV Looks 18.1% Overvalued on GF Value™ Amid Dividend Strength - GuruFocus
AbbVie Completes Acquisition of Apogee Therapeutics - Investing News Network
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma - Investing News Network
AbbVie could take BiTE of Tecvayli market share on Phase III MM win - Yahoo Finance
ABBV Looks 19.1% Overvalued on GF Value™ as Dividend Sustainabil - GuruFocus
AbbVie posts trial win for multiple myeloma drug (ABBV) - Seeking Alpha
AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE) - Seeking Alpha
AbbVie’s $10.9 billion deal adds a late-stage eczema treatment - Stock Titan
AbbVie will stream its healthcare talk live Sept. 15 - Stock Titan
AbbVie (ABBV) Stock Looks Fully Priced Despite A 43% Fair Value Gap - Yahoo Finance
AbbVie Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings - PR Newswire
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks - Barchart.com
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (NYSE:ABBV) Large-Cap Healthcare Strategy Gains Attention - Kalkine Media
Most Of What Moves AbbVie Stock Has Nothing To Do With The Market - Trefis
AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026 - Yahoo Finance
AbbVie Presents New Data Across Lung Cancer Pipeline At WCLC 2026 - marketscreener.com
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline - Investing News Network
AbbVie presents lung cancer data at WCLC 2026 conference By Investing.com - Investing.com Canada
AbbVie will present 90% lung cancer response data; the treatment remains investigational - Stock Titan
AbbVie Stock's Uncoupled Performance - Trefis
Jennison Associates LLC Trims Stake in AbbVie Inc. $ABBV - MarketBeat
Oppenheimer & Co. Inc. Acquires 5,934 Shares of AbbVie Inc. $ABBV - MarketBeat
Hodges Capital Management Inc. Has $4.94 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead - AOL.com
Vest Financial LLC Sells 3,946 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie stock hits fresh 52-week high as earnings strength and guidance lift outlook - Ad-hoc-news.de
AbbVie Inc. $ABBV Shares Sold by D.A. Davidson & CO. - MarketBeat
Benjamin Edwards Inc. Reduces Position in AbbVie Inc. $ABBV - MarketBeat
GUBRA: Biotech revenue normalized post-AbbVie deal; CRO rebounded with 11% growth and profitability - TradingView
GUBRA: Revenue fell after last year's AbbVie deal, but clinical and CRO progress support long-term growth - TradingView
1.32%
자본화:
|
볼륨(24시간):